| Excellence in Synthetic Biology |
Our work strongly aligns with Best SDG Impact, Best Safety, and Best Software tracks. PRESS integrates therapeutic innovation with biosafety safeguards (PemK/I TA system), sustainability, and computational tools. |
Special prizes page here
|
| SDGs |
WFrom the start of our development stage, we went with a definite focus to ensure the sustainability of PRESS and its great impact on the world's future. We have addressed 8 SDGs, considering PRESS's long term impact on them and receiving feedback from various stakeholders.
|
SDGs link
|
| Education |
We focused on vulnerable groups—workers exposed daily to hazards, hospital patients, children, and families—and created targeted materials like parent guides, storybooks, and everyday tips. Our activities were based on three core areas: simplifying synthetic biology, training basic skills, and raising awareness about asthma. Each of our activities was adapted to its intended group, from young children to the elderly. We used workshops, games, songs, comics, and interactive resources instead of lectures To make learning engaging. We also involved policymakers and showed them how synthetic biology could bring therapeutic solutions into the real world. We engaged more individuals on social media, multiple-language podcasts, and translated reports. Finally, we drew it all back to the Sustainable Development Goals, showing how our work was not just about education—how it fit into a bigger vision for health and environment.
|
--
|
| Integrated Human Practice |
We have engaged with multiple stakeholders and divided our project progress into 8 stages:
Inspiration, Problem Identification, Hypothesis Formation, Product design, Ethical Considerations, Social acceptance, Responsibility, and Real-world implementation. These stages are illustrated and documented in a timeline on our Integrated Human Practice page.
|
IHP link
|
| Software |
We developed a protein risk assessment tool to evaluate the potential immunogenicity and toxicity of proteins. In addition, we used software tools to choose which transmembrane protein is stable when fused with an RNA-binding protein. |
Software page here
|
| Entrepreneurship |
We designed a business case for PRESS, considering scalable manufacturing, regulatory feasibility, and potential patient populations, positioning it for translational success. |
Entrepreneurship page here
|
| New Parts |
We contributed two novel parts: DUF4811–L7Ae fusion protein (a TMP–RBP composite enabling vesicle RNA loading) and co-BERA RNA scaffold (dual siRNA therapeutic). These parts are documented as new iGEM contributions. |
Parts page here
|
